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Maria C. Jordan2, Michael C. Fishbein3, Lucio Comai4 & Sita Reddy1
1Department of Biochemistry and Molecular Biology, University of Southern California, Los Angeles, CA 90033, USA, 2Department
of Physiology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA, 3Department of Pathology and Laboratory
Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA, 4Department of Microbiology and
Immunology, University of Southern California, Los Angeles, CA 90033, USA.
Cardiac dysfunction is a prominent cause of mortality in myotonic dystrophy I (DM1), a disease where
expanded CUG repeats bind and disable the muscleblind-like family of splice regulators. Deletion of
muscleblind-like 1 (Mbnl1DE2/DE2) in 129 sv mice results in QRS, QTc widening, bundle block and STc
narrowing at 2–4months of age.With time, cardiac function deteriorates further and at 6months, decreased
R wave amplitudes, sinus node dysfunction, cardiac hypertrophy, interstitial fibrosis, multi-focal
myocardial fiber death and calcification manifest. Sudden death, where no end point illness is overt, is
observed at a median age of 6.5 and 4.8 months in,67% and,86% of male and female Mbnl1DE2/DE2 mice,
respectively. Mbnl1 depletion results in the persistence of embryonic splice isoforms in a network of cardiac
RNAs, some of which have been previously implicated in DM1, regulating sodium and calcium currents,
Scn5a, Junctin, Junctate, Atp2a1, Atp11a, Cacna1s, Ryr2, intra and inter cellular transport, Clta, Stx2, Tjp1,
cell survival, Capn3, Sirt2, Csda, sarcomere and cytoskeleton organization and function, Trim55, Mapt,
Pdlim3, Pdlim5, Sorbs1, Sorbs2, Fhod1, Spag9 and structural components of the sarcomere,Myom1, Tnnt2,
Zasp. Thus this study supports a key role for Mbnl1 loss in the initiation of DM1 cardiac disease.
M
yotonic dystrophy type I (DM1) is a multi-system disorder occurring with an incidence of 158000
worldwide. Three broad forms of DM1 are described, a classic form which has an onset between 10 and
60 years, presenting with myotonia, muscle weakness, smooth and cardiac muscle involvement, CNS
dysfunction, somnolence, endocrine disorders and cataracts, a congenital formwhich is symptomatic at birth and
which progresses tomanifest many of the symptoms of the classic form of the disease and aminimal form that has
its onset after 50 years manifesting with cataracts, myotonia and mild muscle weakness1,2. Heart disease is a well-
established feature of the classic and congenital forms of the disease, with cardiac sudden death a prominent cause
of mortality1,2. Conduction disorders predominate in DM1. First degree heart block or PR prolongation is
commonly observed in DM1 and with increasing time or enhanced disease severity, second and third degree
heart block, QRS, QTc widening and bundle blocks increase in frequency1–5. Poor R wave progression is also a
feature noted in DM16. Left ventricular hypertrophy, dilation and systole dysfunction occur less frequently and
can manifest in the absence conduction disorders1,2,7–10. Histopathological changes include multi focal myofi-
brillar loss, fatty infiltration and fibrosis1,2,6,10. A combination of these features is widely believed to contribute to
sudden cardiac death9–11. Of the electrocardiograph measurements the sum of the QRS duration and PR interval
has been shown to be a strong predictor of mortality in DM112.
The genetic mutation in DM1 is the expansion of a CTG repeat sequence located in the 39 untranslated region
of DMPK and immediately 59 of SIX5 on chromosome 19q13.313,14. In general, larger CTG expansions are
associated with a higher incidence and progression of conduction disease and a trend towards an increase in
serious cardiac events15. Several lines of evidence demonstrate that expression of expanded CUG repeat sequences
plays an important role in the development of key aspects of DM1 pathology16–19. Toxicity associated with
expanded CUG repeats, stems in part from its ability to aberrantly sequester and disable the muscleblind-like
(MBNL) family of RNA splice regulators20–22. In humans,MBNL1 is highly expressed in skeletal muscle and the
heart and shows lower expression in the brain, lung, liver, kidney and pancreas21. In mice, although Mbnl1
expression is more consistent across tissues, the highest expression ofMbnl1 is observed in the heart23. Previous
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experiments have shown that Mbnl1 loss in mice results in skeletal
muscle myotonia and histopathology characteristic of DM1, in con-
junction with cataracts and behavioral alterations that are remin-
iscent of DM1 patients24,25. Mbnl1 is known to play an important
role in regulating the transition of its target RNAs from the embry-
onic splice program to that of the adult26,27. Significantly, previous
studies have implicated the persistence of embryonic Clcn1 splice
isoforms in adult muscle with the development of myotonia both
inMbnl1 deficient mice and in theHSALRDM1mouse model, where
expanded CUG repeat RNA is expressed in skeletal muscle24,28. As
morpholino antisense oligonucleotide targeting prevents aberrant
Clcn1 splicing and reverses myotonia in the HSALR mice, a causal
relationship is established between abnormal Clcn1 splicing and
myotonia29. Taken together these experiments highlight the potential
of physiologically relevant Mbnl1 target RNAs that are aberrantly
spliced to initiate DM1 pathology.
To test the role of Mbnl1 depletion in the development of DM1
cardiac pathology, we deleted Mbnl1 exon 2 (Mbnl1DE2/DE2), which
encodes the ATG codon, in 129 sv mice. This mutation results in
the absence of theMbnl1 protein.Mbnl1DE2/DE2mice show a shortened
life span in conjunction with a variety of conduction defects, cardiac
hypertrophy, fibrosis and multi-focal myocardial fiber death and cal-
cification. Mbnl1 loss results in the enhanced expression of embry-
onic splice isoforms in an RNA network which regulates sodium and
calcium currents, intra and inter cellular transport, cell survival, sar-
comere and cytoskeleton organization and function and encoding
structural components of the sarcomere. These results therefore sup-
port an important role for Mbnl1 depletion in the development of
DM1 cardiac disease and suggest a role for altered splicing in initiat-
ing cardiac pathology.
Results
Development of Mbnl1DE2/DE2 mice. To test the role of MBNL1
deficiency in the development of DM1 cardiac disease we developed
Mbnl1loxE2lox mice in whichMbnl1 exon 2 was flanked by lox sites (Fig.
1a i–iii). Southern blot analysis of targeted 129 sv ES cells is shown in
Fig. 1b. Chimeric animals derived from targeted 129 sv ES cells were
bred to 129 sv wild type animals to derive Mbnl1loxE2lox mice (Fig. 1a
iii). Lox mediated deletion of Mbnl1 exon 2 was achieved by crossing
Mbnl1loxE2lox mice with 129 sv transgenic mice expressing the Cre
recombinase under the control of the protamine 1 promoter30. As
the protamine 1 promoter drives expression of the Cre recombinase
only in the male germ line, a cross between male Mbnl1loxE2lox/Cre mice
and 129 sv wild-type females resulted inMbnl11/DE2mice, which were
subsequently used to obtain Mbnl1DE2/DE2 animals using standard
breeding schemes (Fig. 1a iv). Deletion of Mbnl1 exon 2 was
established by RT-PCR analyses (Fig. 1c). Loss of Mbnl1 protein
in Mbnl1DE2/DE2 mice is shown by western blot analysis (Fig. 1d).
Depletion of Mbnl1 resulted in ,2.5 fold increase in the steady-
state levels of Mbnl2, a splice regulator, which is homologous to
Mbnl1 (Fig. 1d). Analysis of genotype ratios of the progeny of male
and female 129 sv Mbnl11/DE2 mice did not reveal a homozygous
mutant lethal phenotype.
Mbnl1DE2/DE2mice show a short life span.Kaplan-Meyer curves were
developed to examine differences in survival between wild-type
(Mbnl11/1) and Mbnl1DE2/DE2 animals. For this analysis 102 gender
matched mice [Mbnl11/1:51 andMbnl1DE2/DE2: 51; for each genotype
female n5 29 andmale n5 22] were followed for up to 14.9 months
(Fig. 1e–g). There was a statistically significant difference in the
survival curves between Mbnl1DE2/DE2 and Mbnl11/1 mice (x2(1) 5
85.7, p , 0.00001). Median survival time was 6.5 months for
Mbnl1DE2/DE2 males (95% CI 6.48–6.59 months) and 4.8 months for
Mbnl1DE2/DE2 females (95%CI 4.05–5.62months). The survival curves
between Mbnl1DE2/DE2 males and Mbnl1DE2/DE2 females was not
statistically significant (x2(1) 5 2.8, p , 0.10). Death, where no end
point symptoms or illness are overt, was observed in ,67% and
,86% of male and female Mbnl1DE2/DE2 mice respectively. Rectal
prolapse (male Mbnl1DE2/DE2: ,17% and female Mbnl1DE2/DE2: ,10%)
or morbidity from an unknown etiology, where a hunched pos-
ture, weight loss and lethargy were observed prior to death (male
Mbnl1DE2/DE2: ,17% and female Mbnl1DE2/DE2: ,5%) were the other
prominent causes of mortality (Fig. 1f & g). No significant difference
was observed between the body weights of male and female cohorts
of Mbnl11/1 and Mbnl1DE2/DE2 mice at 3–4 and 5–7 months of age
(Supplementary Fig. S2).
Mbnl1DE2/DE2mice showQRS, QTc widening, bundle block and STc
shortening at 2 and 4 months of age.As cardiac conduction defects
are a prominent feature in DM1, surface electrocardiograms were
recorded from male and female Mbnl11/1 and Mbnl1DE2/DE2 mice at
,2 and 4 months of age under light isoflurane anesthesia. Male and
femaleMbnl1DE2/DE2 mice showed a,28% and,40% increase in the
QRS duration, respectively at 2 months (male: p , 0.0001; female:
p , 0.0001) and a ,20% and ,19% increase in QRS duration at 4
months, respectively (male: p5 0.017; female: p, 0.0001) (Fig. 2a &
b, c ii & d ii). Interestingly,,30% ofMbnl1DE2/DE2mice studied at both
ages showed bundle block, where the QRS complex shows an extra
deflection, reflecting the different speeds with which depolarization
occurs in the two ventricles (Fig. 2c iii & d iii). Bundle blocks were not
observed in Mbnl11/1 animals. The QTc interval showed ,13% and
,14% increase in duration at 2 months of age in male and female
Mbnl1DE2/DE2 mice respectively (male: p5 0.001; female: p, 0.0001).
A trend toward QTc widening was observed at 4 months of age in
male and femaleMbnl1DE2/DE2mice (Fig. 2a & b). The STc interval was
,13% and ,22% shorter in male and female Mbnl1DE2/DE2 mice at 2
months of age (male: p 5 0.01; female: p 5 0.0002) and ,14% and
,23% shorter in male and female Mbnl1DE2/DE2 mice at 4 months
(male: p 5 0.031; female: p , 0.0001) (Fig. 2a & b). Male and
female Mbnl1DE2/DE2 mice showed increased heart rates and shorter
RR intervals (Fig. 2a & b). Data are mean and standard deviation.
Recorded values are shown in Supplementary Fig. S3 & S4; Supple-
mentary Table S1 & S2.
ElongatedQTc intervals, diminished Rwave amplitudes and sinus
node dysfunction occur inMbnl1DE2/DE2mice at 6months of age.As
Mbnl1DE2/DE2 mice showed elevated heart rates, we reexamined the
EKGs in male and female mice at 6 months of age subsequent to
anesthesia with ketamine/xylazine, which reduces the heart rate and
can therefore potentially uncover additional conduction defects. As
predicted the heart rate was lower in bothMbnl11/1 andMbnl1DE2/DE2
mice with ketamine/xylazine administration when compared to that
observed with isoflurane (Fig. 3a; Supplementary Table S3). As a
prominent S wave was not observed with ketamine/xylazine, we
measured QTc intervals. With ketamine/xylazine treatment, the QTc
interval showed a prolongation of ,30% and ,66% in Mbnl1DE2/DE2
male (p5 0.006) and female (p5 0.039) mice respectively (Fig. 3a–d).
Data are mean and standard deviation. Recorded values are shown in
Supplementary Fig. S5; Supplementary Table S3.
In these experiments we observed additional QRS waveform abnor-
malities including prolongation of the Tri wave (Transient reentry
current) and sharply diminished R wave amplitudes (Fig. 3b–d).
The prolonged Tri waves are consistent with QRS widening observed
with isoflurane. Significantly, R wave amplitudes were strikingly
smaller in ,90% of the Mbnl1DE2/DE2 mice examined, with the R
waves in most cases not reaching the isoelectric point (Fig. 3b, c &
e). As poor R wave progression can reflect either lead misplacement,
bundle blocks, prior myocardial infarcts, fibrosis or hypertrophy31
we repeated these experiments on a second EKG machine using a
different type of acquisition system and leads and with an alternate
investigator. As similar results were obtained in both cases, poor R
wave amplitudes could reflect bundle blocks, myocardial fiber death,
fibrosis or hypertrophy in Mbnl1DE2/DE2 mice.
www.nature.com/scientificreports
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In ,25% of the Mbnl1DE2/DE2 mice examined we observed elon-
gated RR intervals (,1% to 2.5% of beats over a 20 minute interval),
which reflected $200% increase in the time required for a new P
wave to form. SA node firing was therefore inconsistent and spor-
adically required extended times to fire in Mbnl1DE2/DE2 mice. Such
events were not observed inMbnl11/1mice. A 5minute interval EKG
for a representativeMbnl11/1mouse and anMbnl1DE2/DE2mouse with
elongated RR intervals is shown in Fig. 3f & g.
Mbnl1DE2/DE2mice develop cardiac hypertrophy at 6months of age.
Left ventricular function and chamber dimensions were measured by
ultrasound echocardiography at,2 and 6 month of age in male and
femaleMbnl11/1 andMbnl1DE2/DE2mice (Fig. 4; Supplementary Figure
S6 and Supplementary Table S4 & S5). No abnormalities were noted
at 2 months of age in male Mbnl1DE2/DE2 mice (Mbnl11/1 n 5 3;
Mbnl1DE2/DE2 n 5 3) (Fig. 4a; Supplementary Table S4). Echocar-
diography could not be performed successfully on female mice at 2
Figure 1 | Mbnl1DE2/DE2 mice demonstrate a reduced life-span. (a). The wild type (Mbnl11/1) allele (i), targeting construct (ii),Mbnl1loxE2lox allele (iii) and
Mbnl1DE2 allele (iv) are shown. (b). Southern blot analysis of wild-type and targeted 129 sv ES cell DNA digested with EcoRV and analyzed with a probe
indicted in Panel a. The image shown is cropped. The full-length gel is shown in Supplementary figure S1a. (c). RT-PCR analysis of Mbnl11/1 and
Mbnl1DE2/DE2 heart RNA using primers located inMbnl1 exon 2.Gapdhwas amplified in parallel as an internal control. The images shown are cropped and
full-length gels are shown in Supplementary figures S1b and c. (d). Western blot analysis ofMbnl11/1 andMbnl1DE2/DE2 heart protein lysates using anti-
Mbnl1, anti-Mbnl2 and anti-a-tubulin antibodies. The images shown are cropped and the full-length gels are shown in supplementary figures S1d–f.
(e). Kaplan-Meyer survival curves are shown. A total of 51Mbnl1DE2/DE2mice (22males, 29 females) and a corresponding number ofmale and female wild-
type 129 sv mice were used in this study. Sacrificed mice are indicated by vertical bars. There is a statistically significant difference in the survival curves
between Mbnl1DE2/DE2 and Mbnl11/1 mice (x2(1) 5 85.7, p , 0.00001). The survival curves between Mbnl1
DE2/DE2 males and Mbnl1DE2/DE2 females is not
statistically significant (x2(1) 5 2.8, p , 0.10). (f, g). The recorded causes of death for the male (f) and female (g) Mbnl1
DE2/DE2 mice are indicated.
www.nature.com/scientificreports
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Figure 2 | Mbnl1DE2/DE2 mice show QRS, QTc widening, bundle block and STc shortening at 2 and 4 months of age. (a & b). Relative electrocardiogram
interval values at 2 and 3–4months of age for male (2months: n5 3; 3–4months: n5 3) and female (2months: n5 3; 3–4months: n5 5)Mbnl11/1 and
male (2 months: n 5 3; 3–4 months: n 5 3) and female (2 months: n 5 3; 3–4 months: n 5 5) Mbnl1DE2/DE2 mice are shown. Mice underwent light
isoflurane anesthesia at an inducing dosage of 3% isoflurane in oxygen, which was reduced to 1–1.5% isoflurane in oxygen when measurements were
recorded. Asmouse ECGwaveform shapes are different from human, QRS duration values in this study include the Tri (transient re-entry current) wave,
as it is part of the ventricular depolarization phase. 80–125 beats were analyzed for each mouse. p-values were calculated using the Student’s t-test with
significance set at p # 0.05. p values #0.05 are indicated in red. (c, d). Shown are representative electrocardiogram traces for male (c) and female
(d)Mbnl11/1 andMbnl1DE2/DE2mice at 3–4months of age. QRS expansion (cii & dii) and bundle block (ciii & diii) are observedMbnl1DE2/DE2mice. Bundle
block was observed in,30% ofMbnl1DE2/DE2 mice in both age groups. Recorded values for all intervals are shown in Supplementary Fig. S3 & S4 and in
Supplementary Tables S1 & S2.
www.nature.com/scientificreports
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Figure 3 | Mbnl1DE2/DE2 mice anesthetized with ketamine/xylazine show prolonged QTc intervals, diminished R wave amplitudes and sinus node
dysfunction at 6months of age. (a). Relative electrocardiogram interval values formale (n5 4) and female (n5 6)Mbnl11/1 andmale (n5 3) and female
(n5 5)Mbnl1DE2/DE2 mice at 6 months of age are shown. Mice underwent anesthesia via an intraperitoneal injection of 80 mg/kg ketamine and 8 mg/kg
xylazine in saline. QRS durations include the Tri (transient re-entry current) wave, as it is part of the ventricular depolarization phase inmice. As S waves,
following the triwaves, were not prominent inMbnl11/1 andMbnl1DE2/DE2mice after ketamine/xylazine treatment QRS intervals were notmeasured. Beats
analyzed for each mouse were male (n 5 74) and female (n 5 77) Mbnl11/1 and male (n 5 31) and female (n 5 54) Mbnl1DE2/DE2 mice.
p-values were calculated using the Student’s t-test with significance set at p # 0.05. p-values #0.05 are indicated in red. (b–d). Representative
electrocardiogram traces showing diminished R wave amplitudes in male (b) and female (c) Mbnl1DE2/DE2 mice and expanded Tri-waves in female
(d) Mbnl1DE2/DE2 mice. (e): % Mbnl11/1 and Mbnl1DE2/DE2 mice showing diminished R wave amplitudes. (f, g). Sporadic expansion of RR intervals to
$200% of the average RR interval was observed in,30% of theMbnl1DE2/DE2 mice analyzed [male (n5 4) and female (n5 6)Mbnl11/1mice and male
(n5 3) and female (n5 5)Mbnl1DE2/DE2 mice]. Representative electrocardiogram traces from femaleMbnl11/1 (f) andMbnl1DE2/DE2 (g) mice are shown.
Recorded values for all intervals are shown in Supplementary Fig. S5 and in Supplementary Tables S3.
www.nature.com/scientificreports
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Figure 4 | Mbnl1DE2/DE2 mice show ventricular hypertrophy at 6months of age. (a,b). Relative values for ultrasound echocardiographic measurements at
2 and 6–7months of age formaleMbnl11/1 (2months: n5 3; 6–7months: n5 6) andMbnl1DE2/DE2mice (2months: n5 3; 6–7months: n5 5) are shown.
p-values were calculated using Student’s t-test with significance set at p# 0.05. Values where p# 0.05 are shown in red. (c). 2-D guidedM-Mode images
of representative 20 week male Mbnl11/1 and Mbnl1DE2/DE2 hearts. Ventricular septal thickness and posterior wall thickness are enlarged in the male
Mbnl1DE2/DE2 hearts. The depth from top to bottom is 7 mm. Time is 100 ms/div. Abbreviations: EDD: End-diastolic dimension (green). ESD: End-
systolic dimension (blue). VST: Left ventricular septal thickness (red); PWT: Posterior wall thickness (yellow). Recorded values are shown in
Supplementary Fig. S6 and in Supplementary Tables S4 & S5).
www.nature.com/scientificreports
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months of age due to their small size. At 6 months of age, posterior
wall thickness (PWT) was ,24% greater (p 5 0.007), ventricular
septal thickness (VST),20% greater (p5 0.001) and left ventricular
mass ,34% greater (p 5 0.054) in male Mbnl1DE2/DE2 mice when
compared to male Mbnl11/1 mice (Mbnl11/1 n 5 6; Mbnl1DE2/DE2 n
5 5) (Fig. 4b & c; Supplementary Table S5). Left ventricular function
was not diminished in maleMbnl1DE2/DE2 mice. In females significant
alterations in the left ventricular function and chamber dimensions
were not observed at 6 months of age (Mbnl11/1 n5 3;Mbnl1DE2/DE2
n 5 5). However 2/5 female Mbnl1DE2/DE2 mice tested at 6 months
of age showed ,200–300% increase in left ventricle mass and,30–
60% decrease in left ventricle percent fractional shortening (Supple-
mentary Table S5).
Multi-focal calcification of myocardial fibers and interstitial
fibrosis occur with Mbnl1 depletion at 6 months of age. As poor
Rwave progression can reflect fibrosis or priormyocardial cell death,
a histological analysis ofMbnl11/1 (n5 3) andMbnl1DE2/DE2 (n5 3)
female hearts at 6 months of age was carried out using H&E and E
trichrome stains. Mbnl1DE2/DE2 heart sections showed multi-focal
calcified myocardial fibers and interstitial fibrosis prominently in
the interventricular septum and ventricles (Fig. 5). Such structural
alterations can act as electrical insulators blocking or altering the
course of the action potential depolarization wavefront and thus
contributing to the conduction defects observed in Mbnl1DE2/DE2
hearts at 6 months of age. Histological alterations were not observed
at 2 months of age inMbnl1DE2/DE2 hearts (data not shown). Thus taken
together these analyses demonstrate that Mbnl1 depletion results in
progressive cardiac structural and functional abnormalities (Fig. 6).
Increased embryonic isoform expression in Mbnl1DE2/DE2 hearts.
As Mbnl1 is known to regulate RNA splice transitions during
development, we curated a list of splice events in RNAs reported to
be regulated by Mbnl1 in skeletal muscle and which are expressed at
low levels in the heart26,32 from RNA-seq data obtained from a
129 sv/BL6 Mbnl1 knockout mouse developed by Kanadia and
colleagues24, which was back crossed to wild-type 129 sv mice for
more than 4 generations27 and splice events that are developmentally
regulated in the heart33 as a reference (Fig. 7 & 8; Supplementary Fig.
S7). As Scn5a exon 6a inclusion is developmentally regulated33 and
because recent studies have implicated Scn5a exon 6a missplicing in
the development of DM1 conduction defects and sudden death34 we
studied this splice event and observed enhanced Scn5a exon 6a
inclusion in adult Mbnl1DE2/DE2 hearts in a manner reminiscent
of DM1 and similar to that observed in E18 Mbnl11/1 hearts
(Fig. 7b). Three independent RNAs, Junctin, Junctate and Asph are
Figure 5 | Multi-focal calcification and fibrosis inMbnl1DE2/DE2 hearts at 6
months of age. (a–f). Histological findings in 6month femaleMbnl11/1 (a,
c, e) hearts (n 5 3) and female Mbnl1DE2/DE2 (b, d, f) hearts (n 5 3) are
shown. InMbnl11/1mice fibrosis and calcifications were not observed ((a):
H&E stain312.5, (c): H&E stain3200 and (e): trichrome stain3400). In
theMbnl1DE2/DE2 mice there are multiple foci of calcified myocardial fibers
that appear dark blue in theH&E stained sections (arrows) ((b): H&E stain
340, (d): H&E 3200). The inset shows individual blue dots that likely
represent calcification of individual mitochondria (x400). In panel (f), a
focus of calcification with interstitial fibrosis (light blue lines in this
trichrome stained section, 3400) is shown. Both the calcification and the
fibrosis were multifocal, involving less than 1% of the myocardial tissue,
and were seen in all the Mbnl1DE2/DE2 animals.
Figure 6 | Cardiac pathology observed over 2–6 months of age in Mbnl1DE2/DE2 mice. The heart image shown is obtained from ClipArtist.net (http://
www.clipartlord.com/free-human-heart-clip-art/).
www.nature.com/scientificreports
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Figure 7 | Mbnl1 depletion results in the persistence of embryonic splice isoforms in adult hearts. (a). A cardiac RNA network that is misspliced in
Mbnl1DE2/DE2 hearts is shown. RNAs are categorized by their biological function and Mesh terms. (b–g). Splicing analysis for the indicated RNAs was
performed byRT-PCRwith E18Mbnl11/1 and 4months oldmaleMbnl11/1 (n5 3) andmaleMbnl1DE2/DE2 (n5 3) hearts. Band intensities were quantified
by densitometry. Data are standard error of mean (SEM). p-values were calculated using Student’s t-test with significance set at p # 0.05. Primer
locations, exon numbers and expected band sizes are indicated. The alternatively spliced exons are shown as green boxes. Exon numbers for all genes
except Junctate/Asph are annotated based on Refseq from the UCSC genome browser (NCBI37/mm9); Junctate/Asph is annotated based on the study
carried out by Dinchuck et al (Dinchuk et al., 2000). Scn5a exon 6 and 6A were distinguished by digestion with SacI. The SacI site within Scn5 exon 6A is
indicated in red. Identified novel exons are indicated by asterisks and the sequences of these exons are shown in Supplementary figure S9. The images
shown are cropped. The full-length gels are shown in Supplementary figures S10–S15.
www.nature.com/scientificreports
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derived from a single genomic locus by alternative splicing35. Asph
Exon 4a inclusion is diminished in E18 Mbnl11/1 hearts and in adult
Mbnl1DE2/DE2 hearts when compared with adult Mbnl11/1 hearts
(Fig. 7b). Asph Exon 4a is present in one of four alternatively
spliced Asph isoforms, one of two Junctate isoforms and in both
alternatively spliced forms of the Junctin RNA in the mouse heart35.
To confirm that the two alternatively spliced isoforms of junctin (Asph
Exon1a–5a and Asph Exon 1–5a) show constitutive inclusion of exon
4a in 129 sv mice, we examined the two known Junctin isoforms by
RT-PCR. A single band was observed when primers were located in
Asph exon 1 and exon 5a and when primers were located inAsph exon
1a and exon 5a (Supplementary Fig. S8), demonstrating that exon 4a is
included in both Junctin RNA isoforms. As Asph exon 4a inclusion is
diminished in adultMbnl1DE2/DE2 hearts, this splice error is predicted to
decrease Junctin levels. Steady-state levels of Junctin (Exon 1a–5a) and
Junctin (Exon 1–5a)mRNA levels measured by qPCR were,70% and
,80% reduced respectively, inMbnl1DE2/DE2 hearts when compared to
controls (Fig. 8a–c; Supplementary Fig. S8). Diminished Atp2a1 exon
22 inclusion, enhanced inclusion Atp11a exon 28a, diminished in-
clusion of Cacna1s exon 29 and enhanced Ryr2 exon 5 only inclu-
sion (Fig. 7b) are observed in Mbnl1DE2/DE2 hearts and E18 Mbnl11/1
hearts when compared with adult Mbnl11/1 hearts. Thus RNAs
regulating sodium and calcium currents show increased expression
of embryonic splice isoforms in Mbnl1DE2/DE2 hearts. With Mbnl1
depletion, three RNAs involved in inter and intra cellular transport
Clta, Stx2 and Tjp1/Zo1 are aberrantly spliced in a manner remini-
scent of E18 Mbnl11/1 hearts (Fig. 7c). Atp2a2 exon 18 and Kcnip2
exon 4 splicing was not altered in Mbnl1DE2/DE2 hearts (Fig. 8; Supple-
mentary Fig. S7).
We examined splice site choice in Titin (Ttn) and Myomesin I
(Myom1) RNAs, which encode PEVK or PEVK-like domains that
contribute to protein elasticity and can therefore regulate the compli-
ance of the myocardium36–40. In addition, we examined splice events in
Capn3, Sirt2, Csda, Clk2 andMadd, which are reported to regulate cell
viability41–46. We did not observe missplicing of Ttn exon 9, Ttn exon
311, or Ttn exons 114–119, 121–124 or 171–183 inMbnl1DE2/DE2 hearts
(Supplementary Fig. S7). Mbnl1 loss resulted in enhanced inclusion of
Myom1-exon 18 (Fig. 7d), diminished Capn3 exon 16 and 17 inclu-
sion, enhanced Sirt2 exon 2 inclusion and enhanced Csda exon 6
inclusion (Fig. 7e). Mbnl1 depletion did not alter Madd exon 5 or
Clk2 exon 4 splicing (Fig. 8; Supplementary Fig. S7). A novel splicing
event detected in MyomI is shown in Supplementary Fig. S9.
We tested splice events in additional RNAs encoding sarcomere
proteins (Tnnt2, Ldb3/Zasp), proteins regulating sarcomere and
Figure 8 | Tabulation of splice errors in Mbnl1DE2/DE2 hearts. (a). Splice events examined in this study are tabulated. PSI: percent spliced in; NAS:
Alternative splicing not detected by RT-PCR analysis. (b, c). Steady-state Junctin (E1a–5a) and Junctin (E1–5a)mRNA levels were analyzed by qPCR in
E18Mbnl11/1 hearts, 4monthmaleMbnl11/1 (n5 3) and 4monthmaleMbnl1DE2/DE2 (n5 3) hearts. Exon numbers and primer positions are shown. Data
are standard error ofmean (SEM). p-values were calculated using Student’s t-test with significance set at p# 0.05. Values where p# 0.05 are shown in red.
(d). Potential relationships between splice errors and the cardiac pathology observed are indicated. The heart image shown is obtained fromClipArtist.net
(http://www.clipartlord.com/free-human-heart-clip-art/).
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cytoskeleton assembly and function (Ablim1, Nrap, Mapt, Trim55/
Murf2, Pdlim3, Pdlim5, Sorbs1, Sorbs2, Spag9, Fhod1 and Arhgef7).
From this group of RNAs, Tnnt2, Ldb3/Zasp, Trim55,Mapt, Pdlim3,
Pdlim5, Sorbs1, Sorbs2, Fhod1 and Spag9RNAs are aberrantly spliced
in Mbnl1DE2/DE2 hearts, in a manner similar to that observed in E18
Mbnl11/1 hearts (Fig. 7 d & f). Arhgef7 exon 16, Nrap exon 12 and
Ablim1 exon 18 splicing was not altered inMbnl1DE2/DE2 hearts (Fig. 8;
Supplementary Fig. S7). Novel splice events detected in Pdlim3/Alp
are shown in Supplementary Fig. S9.
Lastly, we examined splice events in RNAs known to play a role
in heart development (Tbx5)47, myogenesis (Fbxo40)48 and splicing
(Mbnl2)22. We observe enhanced inclusion ofMbnl2 exon 6 (Fig. 7g),
but splicing of Tbx5 exon 6 and Fbxo40 exon 2 was not altered in
Mbnl1DE2/DE2 hearts (Fig. 8; Supplementary Fig. S7). The RNA net-
work where embryonic isoforms persist in adultMbnl1DE2/DE2 heart is
shown in Fig. 7a.
Discussion
Mbnl1 depletion in 129 sv mice results in QRS and QTc widening,
STc shortening, bundle blocks, diminished R wave amplitudes and
SA node dysfunction in conjunction with cardiac hypertrophy, fib-
rosis, multi-focal myofibrillar death, calcification and sudden death.
Concurrently Mbnl1 depletion results in the enhanced expression of
embryonic splice isoforms of RNAs regulating sodium and calcium
currents (Scn5a, Asph, Junctin, Junctate, Atp2a1, Atp11a, Cacna1s,
Ryr2), intra and inter cellular transport (Clta, Stx2 and Tjp1/Zo-1),
compliance of the myocardium (Myom1), cell survival (Capn3, Sirt2,
Csda) cytoskeleton and sarcomere assembly and function (Trim55,
Mapt, Pdlim3, Pdlim5, Sorbs1, Sorbs2, Fhod1 and Spag9) and encod-
ing sarcomere structural proteins (Tnnt2, Ldb3). As several of these
features are observed in DM11–12,32,34,49,73, this study supports a key
role for Mbnl1 depletion in the initiation of DM1 cardiac pathology.
We examined the cardiac pathology thatmanifests over a period of
two to six months inMbnl1DE2/DE2mice and observe that QRS widen-
ing manifests at two months, is sustained at 4 months of age and that
other distinctive QRS waveform abnormalities manifest at 6 months
of age. Bundle block is observed in the 2–4 month period.
Interestingly, QRS and QTc widening were more prominent at 2
months when compared to 4 months in Mbnl1DE2/DE2 mice. This
may reflect early mortality of the more severely affected animals
(Fig.1e). Interestingly, as with DM1, where functional and structural
involvement is associated with age and the male gender10,15, signifi-
cant cardiac hypertrophy manifested at 6 months of age in male
Mbnl1DE2/DE2 mice, with females showing a trend towards hyper-
trophy. In contrast, QTc widening in DM1 is associated with being
female and older5. Reminiscent of this feature, QTc widening was
more prominent at 6months of age in femaleMbnl1DE2/DE2micewhen
compared to males. Cardiac histology in Mbnl1DE2/DE2 mice showed
similarities with DM1with themanifestation of multi-focal calcifica-
tion and fibrosis located primarily in the septum and ventricles at 6
months of age10. Such histological alterations could underlie the
conduction defects observed at 6months. The concurrent manifesta-
tion of conduction defects, ventricular hypertrophy and histological
abnormalities may therefore serve to increase the predisposition to
sudden cardiac death with Mbnl1 depletion. In this regard it is of
interest to note that QRS, QTc widening and echocardiographic
abnormalities have been implicated as risk factors for sudden death
in DM1 patients5,9–12.
Our current and previous analysis of DM1 mouse models shows
that DM1 cardiac pathology can result from DMPK, SIX5 and
MBNL deficits50–53. CTG expansion is known to result in an ,20–
75% decrease in DMPK54,55 and,50% decrease in SIX5 levels56,57, as
a consequence of DMPK RNA retention in the nucleus and epige-
netic silencing of the SIX5 allele linked to the expanded CTG tract.
We have shown that first, second and third degree AV blockmanifest
in mice as a function of time and diminishing Dmpk dosage ranging
from 50–100% loss50–52. In other experiments we have shown that a
Six51/2mice show QRS widening53. As almost a complete sequest-
ration of MBNL1 in CUG foci can occur in DM1 patient hearts with
advanced disease49, we examined the consequence of complete
Mbnl1 loss in the mouse heart and observe that Mbnl1 loss plays a
key role in initiating the electro and echocardiographic abnormalities
detailed above. In a recent study, Lee and colleagues have shown that
combinatorial loss of Mbnl1 and Mbnl2 in 129 sv/BL6 mice
(Mbnl12/2/Mbnl21/2) show both PR expansion or first degree
heart block in conjunction with QRS expansion58. Taken together
these results demonstrate that losses in DMPK, SIX5, MBNL1 and
MBNL2 can recreate a great number of the prominent cardiac fea-
tures observed in DM1. As systole dysfunction and diminished ejec-
tion fraction is not observed in these mouse models it is unclear if
additional losses in Mbnl3 will be required to fully recapitulate both
the echo and electrocardiographic abnormalities described in DM1.
Significantly, CUG repeat expression also results in elevated steady
state levels of the RNA binding protein, Cug-bp118 and transgenic
mice that acutely express Cug-bp1 levels at levels that are,4–8 fold
higher than endogenous levels show PR and QRS prolongation,
dilated cardiomyopathy, systolic dysfunction with reduced ejection
fractions and widespread necrosis with death occurring 7 days post
induction of Cug-bp1 expression59. As the acute induction of high
levels of CUG-BP1 is not observed inDM1 patients, it is important to
examine the nature of the pathology that manifests with the con-
stitutive expression of Cug-bp1 in mice, at levels that are similar to
that observed in DM1 patient hearts. Such experiments will allow
better comparisons to bemade between the pathology resulting from
CUG-BP1 over-expression and reduced levels of DMPK, SIX5 and
the MBNL proteins. As Cug-bp1 over-expression alters splice site
choice in a manner that partially overlaps with that observed with
Mbnl1 loss60, pathophysiology shared by both mouse models has
been hypothesized to result from similar RNA defects, while unique
features and the disease trajectory of the cardiac pathology observed
in Mbnl1DE2/DE2 hearts are predicted to result from RNA defects
resulting exclusively from Mbnl1 loss.
Lee et al.58 have demonstrated that Mbnl1 exon 2 deleted mice
developed by Kanadia and colleagues24 on a mixed 129 sv/BL6 back-
ground do not show cardiac pathology (annotated asMbnl12/2 by
the authors). These animals showed modest to severe splice errors
in 8 RNAs. The lack of a cardiac phenotype was attributed to a
compensatory increase in Mbnl2 steady-state levels in 129 sv/BL6
Mbnl12/2 hearts. Reduction in Mbnl2 levels in conjunction with
Mbnl1 loss in 129 sv/BL6Mbnl12/2/Mbnl21/2mice resulted in a
decrease in life span and the development of cardiac pathology com-
parable to that described for the 129 sv Mbnl1DE2/DE2 mice in this
study. It should be noted, that both in this study and that of Lee
and colleagues Mbl1 exon 2, which encodes the Mbnl1 translational
start site, was deleted. Furthermore, both 129 sv/BL6 Mbnl12/2
and 129 sv Mbnl1DE2/DE2 hearts show an increase in steady-state
Mbnl2 levels (Fig. 1d). However, when Tnnt2 exon 5 inclusion, a
splice error studied in all three mouse strains is examined interesting
differences come to light. In 129 sv/BL6Mbnl12/2 hearts, aberrant
Tnnt2 exon 5 inclusion is ,20%. In contrast both 129 sv/BL6
Mbnl12/2/Mbnl21/2 hearts and 129 sv Mbnl1DE2/DE2 hearts show
,70–85% inclusion of Tnnt2 exon 5 (Fig. 7d). In contrast Arhgef7was
misspliced in 129 sv/BL6 Mbnl12/2 hearts but not in 129 sv
Mbnl1DE2/DE2 hearts (Supplementary Fig. S7 and Ref. 58). These results
demonstrate that mouse strain differences can alter the outcome of
both Mbnl1 mediated splicing and cardiac pathology. This obser-
vation is significant, as DM1 is recognized to be a disorder character-
ized by significant phenotypic variability associated with CTG tract
expansions of similar lengths61. Our results support the hypothesis
that modifier genes regulating Mbnl1 function can strongly influence
disease trajectory in DM1 patients. Thus comparison of these two
mouse models provides a unique opportunity to identify modifiers
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that regulate the severity of DM1 pathology. Identification of such
modifier genes will allow better predictions to be made for disease
trajectories in individual patients and provide mechanistic insights
into Mbnl1 regulation in vivo.
Splice events that we have tested inMbnl1DE2/DE2 hearts are shown
in Fig. 7 & 8. As several lines of evidence point to alterations in
myocyte force generation, force transmission via the cytoskeleton
and calcium homeostasis as critical signals that result in cardiac
remodeling and disease62, interesting correlations exist between the
RNAs that show aberrant splicing and theMbnl1DE2/DE2 heart pheno-
type. A subset of splice events that are noteworthy with respect to the
pathology observed in Mbnl1DE2/DE2 hearts are discussed. A central
pathology resulting from Mbnl1 loss is conduction defects, which
can reflect both functional and structural cardiac abnormalities.
With regard to functional deficits, Scn5a and Junctin/Junctate mis-
splicing is of interest. Adult Mbnl1DE2/DE2 hearts show ,2.5 fold
increase in the inclusion of Scn5a exon 6a (,12%) (Fig. 7b).
Inclusion of exon 6a in Scn5a results in a sodium current loss of
function phenotype, which manifests with a depolarized shift in
steady-state activation, slower kinetics of activation and inactivation,
slower recovery from inactivation, an increase in the time for the
sodium currents to peak and reduced channel availability63. This
splice error has been recently reported in DM1 patients and is pre-
dicted to contribute to sudden death in this patient population34. As
the QRS interval duration is influenced by the time for sodium cur-
rents to peak64, enhanced inclusion of Scn5a exon 6a may underlie
QRS widening in Mbnl1DE2/DE2 mice. Significantly, QRS widening is
known to greatly increase the chance of sudden death in the general
human population with cardiomyopathy and in DM1 patients11,12,65.
Additionally, Scn5a loss of function mutations are known to cause
sick sinus syndrome66 where reduction in the flow of sodium ions
alters the ability of the SA node to develop and spread electrical
signals. Therefore, this splice error may be of significance both with
respect to SA node dysfunction and QRS widening in Mbnl1DE2/DE2
mice.Mbnl1DE2/DE2 hearts show altered splicing of Junctate and reduc-
tion in Junctin mRNA levels. As aberrant levels of junctin and junc-
tate are known to alter calcium homeostasis and result in arrhythmia
and sudden death67–70, it is possible that these splice errors can fur-
ther enhance the chance of sudden death inMbnl1DE2/DE2mice. Lastly,
it is of interest to note that Ryr2 mutations have been reported to
cause polymorphic ventricular tachycardia and that Cacna1s mis-
splicing results in aberrant gating of Ca(V)1.1 calcium channel71,72.
Thus alterations in sodium and calcium currents may underlie the
conduction defects and sudden death observed inMbnl1DE2/DE2 mice
Mbnl1 depletion leads to multi-focal myofibrillar death, calcifica-
tion and fibrosis prominently in the septum and ventricles (Fig. 5).
These structural alterations can act as electrical insulators to result in
conduction blocks. Enhanced myocyte death or fibrosis in the His-
Purkinje system or ventricle can lead to diminished R wave ampli-
tudes andQTc widening.With regard to the development of fibrosis,
it should be noted that whole body inactivation of the splice regu-
lator, RBM20 in mice results in altered titin splicing with the persist-
ence of large, elastic embryonic N2BA titin isoforms in adult mouse
hearts37. This change increases myocardial compliance and the
reduced recoil of flaccid titin filaments is predicted to play a causal
role in an adaptive increase in collagen biosynthesis and the develop-
ment of fibrosis, arrhythmias and sudden death in RBM20 knockout
mice36,37. RNAs encoding the large embryonic N2BA titin isoforms
are not observed in adult Mbnl1DE2/DE2 hearts. In contrast, both in
DM1 patient hearts and inMbnl1DE2/DE2 hearts, enhanced expression of
embryonic myomesin I, an isoform that is more elastic and thus more
compliant than the adult isoform of myomesin I is observed38–40,73. As
myomesin is adapted to bear mechanical stress and M-line proteins
must be stretched and coiled during muscle contraction and relaxa-
tion, increased elasticity of embryonic Myomesin I is predicted to
trigger an adaptive increase in fibrosis in a manner similar to that
predicted for titin missplicing in RBM20 deficient mice36–40. We
observe that Mbnl1 depletion results in diminished inclusion of
Capn3 exon 16 & 17. Capn3 is a calcium dependent protease that
binds to titin and cleaves several cytoskeletal proteins. Absence of
Capn3 mediated substrate cleavage has been shown to result in
muscle fiber death41. Analysis of Capn3 splice variants has shown
that Capn3 exon 16 is required for fodrin cleavage42. Thus the dimin-
ished inclusion of Capn3 exon16, is of interest with respect to the
cardiac myofiber death observed in Mbnl1DE2/DE2 hearts.
We observe a very high rate of Tnnt2 exons 4 and 5 inclusion in
Mbnl1DE2/DE2 mice. This inclusion pattern is more marked than that
observed in E18 Mbnl11/1 hearts (Fig. 7d). The importance of this
isoform switching in the development of cardiac hypertrophy, is
underscored by an intron 3 polymorphism that alters exon 4 splicing
and predisposes to left ventricle hypertrophy74. Mutations in Zasp/
Cypher in humans are associated with cardiac hypertrophy75 and re-
expression of embryonic RNA isoforms ofMyomI,Asph,Mbnl2 have
been reported in rat models of cardiac hypertrophy76. Lastly, we
observe a cascade of splice errors reminiscent of embryonic splice
patterns in RNAs regulating cytoskeleton and sarcomere assembly
and function including Trim55, Mapt, Pdlim3, Pdlim5, Sorbs1,
Sorbs2, Fhod1 and Spag9 in Mbnl1DE2/DE2 hearts. We speculate that
the aberrant isoform stoichiometry of these proteins could enhance
myocyte fragility, death or maladaptive hypertrophy inMbnl1DE2/DE2
hearts. Elucidation of the causal role of these splice errors in DM1
cardiac pathology in future studies should provide important mech-
anistic insights into DM1 cardiac disease.
Human heart failure is associated with high morbidity and is an
end-stage of various forms of heart disease77. Several characteristic
changes are observed in end-stage failing hearts, with the best docu-
mented alterations at the molecular and organ level being a tran-
scriptional and post-transcriptional splicing reprogramming to
resemble that of the embryonic heart, various degrees of hyper-
trophy, mitochondrial dysfunction, alteration of sarcomere and
cytoskeleton architecture, aberrant calcium handling, increase in
myocyte cell death by apoptosis or necrosis and enhanced extracel-
lular matrix formation78. Although the switchback to an embryonic
splice program is well established in heart failure its potential role in
either accelerating healing or in triggering further dysfunction and
death is unclear. For this reason there has been a great interest in
identifying and characterizing splice regulators that control embry-
onic to adult splice transitions. Although RBM20, ASF/SF2 and SC35
were initially regarded as potential candidates that regulate the trans-
ition of embryonic to adult splice programs, it is now clear that the
MBNL1 and CUG-BP1, which plays an opposing role to MBNL1,
play a central role in this phenomenon. Results from this study
suggest that re-expression of embryonic isoforms in heart failure
may be maladaptive.
It is significant to note that the persistence of the embryonic splice
program observed in Mbnl1DE2/DE2 hearts is reminiscent of that
observed in human heart failure. Indeed several of the classicmarkers
for human heart failure including re-expression of embryonic RNA
splice isoforms ofMyom I, Tnnt2 and low Junctin levels characterize
theMbnl1DE2/DE2 hearts33,70,79,80. Interestingly, global analysis of splice
changes in human heart failure demonstrates a significant overre-
presentation of MBNL motifs in sequences flanking differentially
spliced exons79. It should be noted that MBNL1 levels increase and
CUG-BP1 levels decrease during heart development60 andmolecular
events that change these trajectories can reinstate embryonic splice
programs in the adult heart. As alterations inMBNL1 and CUG-BP1
levels or function can result in splice errors, cardiac dysfunction and
death, it will be particularly important to understand the molecular
events that regulate the activity of this pair of proteins in heart
disease. Such studies are predicted to uncover novel therapeutic ave-
nues that diminish the rates of progression to heart failure and death
in both DM1 patients and in the general population.
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Methods
Ethics Statement. All experiments were performed in accordance with the
institutional guidelines of both the University of Southern California (USC), and the
University of California, Los Angeles (UCLA). The USC protocol was approved by
the Institutional Animal Care and Use Committee at the University of Southern
California, Los Angeles (Protocol number: 10347). The UCLA protocol (99-028) was
approved by the UCLA Office of Animal Research Oversight.
Statistical analysis. Kaplan-Meyer curves were developed to examine differences in
survival between Mbnl11/1 and Mbnl1DE2/DE2 mice, testing the difference in survival
using the Mantel-Cox (log rank) test and adjusting for Mbnl1DE2/DE2 mice that were
sacrificed. Further modeling examined the potential of a gender difference within the
Mbnl1DE2/DE2 mice. Analyses were performed in SPSS (v.21); a 5 0.05.
Surface ECG Recording. Electrocardiograms were obtained for at least 15 minutes
from each mouse either under light isoflurane anesthesia or subsequent to ketamine/
xylazine administration (ketamine 80 mg/kg and xylazine 8 mg/kg) by respectively
inserting two Pt needle electrodes (Grass Technologies, WestWarwick, RI) or two 29
guage needle electrodes (ADInstruments, Colorado Springs, CO) under the skin in
the lead II configuration. Isoflurane induced ECG data were amplified (Grass
Technologies) and then digitized for analysis with HEM V4.2 software (Notocord
Systems, Croissy sur Seine, France). ECG data recorded through ketamine/xylazine
administration were amplified using a Bio Amp (ADInstruments) and digitized using
Labchart7 software (ADInstruments). Since mouse ECG waveform shapes are
different from human, QRS duration values in this study include the Tri (transient re-
entry current) wave, as it is part of the ventricular depolarization phase. T waves tend
to be negative going in mice. To correct for the variability in the heart rate observed
between mouse genotypes, corrected QTc and STc intervals were calculated using
Bazett’s Formula: QTc 5 QT/ RR and STc 5 ST/ RR.
Ultrasound Echocardiography. Left ventricular (LV) size, mass, wall thickness,
ventricular and valve function and blood flow were assessed using methods
previously described81,82. Measures of chamber dimensions [end-diastolic dimension
(EDD); end-systolic function (ESD); ventricular septal thickness (VST); posterior
wall thickness (PWT)], heart rate, ventricular function [left ventricular % fractional
shortening (LV%FS); velocity of circumferential fiber shortening (Vcf); and left
ventricular ejection fraction (LVEF)] and the early (E) and atrial (A) diastolic filling
(E/A ratio) were obtained from mice lightly anesthetized with isoflurane (1.0–1.5%)
to permit physiological levels of function.
Morphometry & Histology. All morphometry and histology experiments were
carried out primarily as described by Jordan and colleagues82.
RNA analysis. Heart tissue was pulverized under liquid nitrogen. Total RNA was
prepared using Trizol (Invitrogen, USA) according to the manufacturer’s protocol.
RNA from E18 heart tissues was obtained from Zyagen Inc. cDNA was synthesized
from 5 mg of total RNA using the cDNA synthesis kit (Thermo Scientific., USA).
cDNAs were used for splicing assays using primers and PCR conditions described in
Supplementary Table S6. The relative band intensities were measured by
densitometry analysis using Gene Tool (Syngene Inc., USA). To identify novel splice
isoforms, bands were excised and DNA was extracted using gel extraction kits
(Qiagen, USA). Extracted DNAs were cloned into pGEM-T Easy Vector (Promega,
USA) according to the manufacturer’s protocol. The DNA inserts were sequenced
using T7 and SP6 promoter sequencing primers (Integrated DNA Technologies Inc,
USA). To measure the level of exon 6a inclusion in Scn5a, amplified PCR products
were visualized on 2% agarose gel followed by digestion with Sac I (NEB, USA) for 2 h
at 37uC. The relative band intensities were measured by densitometry analysis using
Gene Tool.
Western blot analysis. Mouse heart tissues were pulverized in liquid nitrogen and
whole cell lysates were prepared by homogenization in modified RIPA buffer
(Upstate Inc., USA). Protein extracts were subjected to Western blot analysis with
anti-Mbnl1 described by Holt and colleagues83. Anti-Mbnl2 and anti-Tubulin
antibodies were obtained from Santa Cruz Biotechnology Inc. USA.
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